NEWARK, Calif., May 11, 2016 (GLOBE NEWSWIRE) — Cymabay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies to treat metabolic diseases with high unmet medical need, today provided recent corporate highlights and announced financial results for the quarter ended March 31, 2016. “The first quarter of 2016 was marked by continued momentum for our two lead development programs, MBX-8025 for rare orphan diseases, and arhalofenate for gout,” said Dr. Harold Van Wart, Chief Executive Officer of CymaBay Therapeutics.  “We were pleased to have seen positive signs of efficacy in our pilot Phase 2 study of MBX-8025 in […]